Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 2/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 4/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCND1 | P24385 | 2/20 | 0.36 |
| ▸ | CCND2 | P30279 | 2/20 | 0.36 |
| ▸ | CCND3 | P30281 | 2/20 | 0.36 |
| ▸ | WEE1 | P30291 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035819 | 0.84 | CAMK2D (0.42) | CAMK2DPAK4PKN1TNK2SRC | |
| SCHEMBL15035047 | 0.83 | CAMK2D (0.45) | CAMK2DPAK4PKN1TNK2SRC | |
| SCHEMBL15034942 | 0.80 | CAMK2D (0.46) | CAMK2DPAK4PKN1TNK2SRC | |
| SCHEMBL15035698 | 0.80 | CAMK2D (0.45) | CAMK2DTNK2SRCAXLFGFR1 | |
| SCHEMBL15035911 | 0.79 | CAMK2D (0.45) | CAMK2DPAK4PKN1TNK2SRC | |
| SCHEMBL15036308 | 0.76 | CHEK1 (0.39) | TNK2SRCEGFRFGFR1CDK4 | |
| SCHEMBL15036327 | 0.73 | CAMK2D (0.45) | CAMK2DPAK4PKN1TNK2SRC | |
| SCHEMBL15035359 | 0.72 | CAMK2D (0.44) | CAMK2DTNK2SRCAXLEGFR | |
| SCHEMBL15258247 | 0.72 | CAMK2D (0.40) | CAMK2DPAK4PKN1TNK2SRC | |
| SCHEMBL15034923 | 0.72 | CDK4 (0.38) | AXLEGFRFGFR1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | CAMK2D 125/4885PAK4 5/4885PKN1 604/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CAMK2D 469/4885PAK4 5/4885PKN1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.